4D Surgical

MRI-guided robotics platform for minimally invasive brain procedures, enabling universal physical access to the brain.

Website: https://www.4dsurgical.com/

Cover Block

Open sources

Field Value
Name 4D Surgical
Tagline MRI-guided robotics platform for minimally invasive brain procedures, enabling universal physical access to the brain [4D Surgical, retrieved 2026]
Headquarters San Francisco, United States [Crunchbase]
Founded 2024 [Crunchbase]
Stage Seed [Version One Ventures, November 2026]
Business Model Hardware + Software
Industry Healthtech
Technology Robotics
Geography North America
Growth Profile Venture Scale
Founding Team Lorne Hofstetter, Roman Devengenzo, Blake Zimmerman [4D Surgical, retrieved 2026]
Funding Label Seed
Total Disclosed ~$8,000,000 [Version One Ventures, November 2026]

Links

Open sources

What an Investor Needs First

PUBLIC 4D Surgical is building an MRI-compatible robotic platform for minimally invasive brain procedures, and it is worth attention now because the company has moved from technical concept into a financed seed-stage effort with a stated path toward FDA work [4D Surgical, retrieved 2026] [Version One Ventures, November 2026] [Axios Pro, November 2026]. Founded in 2024 in San Francisco, the company is positioning around a narrow but consequential problem: gaining physical access to the brain during image-guided procedures, initially in stereotactic neurosurgery with live MRI feedback [4D Surgical, retrieved 2026] [Crunchbase] [LinkedIn, retrieved 2026].

The product claim is ambitious but specific. 4D Surgical says its robotic arm is designed to operate inside an MRI scanner, where conventional robotic systems face magnetic interference constraints, and public materials tie that capability to future delivery of electrodes, drugs, devices, and gene therapies rather than to a general-purpose surgical robotics thesis [4D Surgical, retrieved 2026]. Independent technical support is still limited, but a Communications Engineering report states that Lorne Hofstetter and colleagues designed a non-magnetic electromagnetic servomotor and tested it in a robot operating in a clinical MRI during imaging, which gives the core engineering premise more weight than a website claim alone [Communications Engineering, retrieved 2026].

The founding team reads as unusually aligned to the problem the company is trying to solve, at least on paper. Chief executive Lorne Hofstetter is presented as a physician-engineer with prior experience at GE Healthcare and GE Global Research, co-founder Roman Devengenzo brings hardware experience that includes Intuitive Surgical, Google, and Johnson & Johnson, and co-founder Blake Zimmerman is described as coming from MRI-guided procedures, computer vision, and medical-image analysis [4D Surgical, retrieved 2026] [Lorne Hofstetter - 4D Surgical | LinkedIn, retrieved 2026] [Roman Devengenzo - 4D Surgical | LinkedIn, retrieved 2026] [Blake Zimmerman - 4D Surgical | LinkedIn, retrieved 2026].

The company is a hardware-plus-software bet and remains very early by operating evidence. Version One Ventures announced an $8 million seed round in November 2026 with participation from Humba Ventures, Also Capital, Julian Capital, Mythos Ventures, Inflect Capital, and University of Toronto-related backers, while Axios Pro reported that 4D Surgical plans to raise $30 million in the second half of 2027 to begin the FDA-clearance process [Version One Ventures, November 2026] [Axios Pro, November 2026] [Inflect Capital]. LinkedIn and Prospeo both place the team at roughly 1 to 10 employees, consistent with a company still in technical buildout rather than commercial scale-up [LinkedIn, retrieved 2026] [Prospeo.io, retrieved 2026].

What matters over the next 12 to 18 months is less narrative than proof. Investors should watch for repeatable technical validation beyond company and investor channels, clearer regulatory sequencing, and any evidence that leading neurosurgical centers are willing to engage before clearance, because the current public record does not yet show named hospital customers or commercial deployments [Axios Pro, November 2026] [4D Surgical, retrieved 2026].

Claim stands unchecked -- This section relies materially on company website claims for product scope and founder biographies, with partial corroboration from Version One Ventures, Axios Pro, LinkedIn, and Communications Engineering.

Taxonomy Snapshot

Axis Value
Stage Seed
Business Model Hardware + Software
Industry / Vertical Healthtech
Technology Type Robotics
Geography North America
Growth Profile Venture Scale
Founding Team Co-Founders (3+)
Funding Seed, total disclosed about $8,000,000

Inside the Company

PUBLIC

4D Surgical appears early, but the contours of the company are already fairly clear. The business was founded in 2024 and is based in San Francisco, where it is positioning itself around MRI-guided robotics for minimally invasive brain procedures, with the stated aim of creating "universal brain access" through an MRI-compatible platform [Crunchbase] [4D Surgical, retrieved 2026].

The public milestone record is short and mostly company- or investor-led. The company website describes a platform built to deliver therapies anywhere in the brain using MRI-guided robotics [4D Surgical, retrieved 2026]. Crunchbase lists 4D Surgical as a 2024-founded company and records an $8 million seed round in November 2026, while the company's investor syndicate publicly includes Version One Ventures, Humba Ventures, Also Capital, Julian Capital, Mythos Ventures, Inflect Capital, University of Toronto, and University of Toronto Entrepreneurship [Crunchbase] [4D Surgical, retrieved 2026].

What is still missing from the public record matters as much as what is present. No legal entity detail or state filing appears in the provided source set, and the company has not surfaced a longer operating history, commercial launch timeline, or customer footprint through these public materials [Crunchbase] [4D Surgical, retrieved 2026]. For now, the overview is that of a newly formed surgical robotics company with a defined technical ambition and one disclosed seed financing, rather than a business with an established commercialization record [Crunchbase] [4D Surgical, retrieved 2026].

Claim stands unchecked -- This section relies primarily on company website and Crunchbase records, with no corroborating state filing or legal entity disclosure in the provided public sources.

Under the Hood

MIXED

The technical claim is straightforward, and unusually specific for a seed-stage medtech company. 4D Surgical says it is building an MRI-compatible robotic platform for minimally invasive, image-guided brain procedures, with an initial focus on stereotactic neurosurgery performed with live MRI feedback [4D Surgical, retrieved 2026]. The company frames the broader ambition as "universal physical access to the brain," and says the system is intended over time to support delivery of electrodes, drugs, devices, and gene therapies [4D Surgical, retrieved 2026].

The differentiator, if the public materials hold up in clinical and regulatory review, is operation inside the MRI bore rather than adjacent to it. 4D Surgical states that its robotic arm is designed to function inside an MRI scanner, where conventional motors and robotic systems cannot safely operate because of magnetic interference, and says the system is built to work in a magnetic field described as 50,000 times stronger than the Earth's while maintaining a silent RF footprint [4D Surgical, retrieved 2026]. An academic-adjacent proof point exists beneath the company marketing: Communications Engineering reported that Lorne Hofstetter and colleagues designed a servomotor from non-magnetic components and tested it in a robot operating in a clinical MRI during imaging [Communications Engineering, retrieved 2026]. Separately, Children's National has described BrainBot as an MRI-compatible robotic system for real-time minimally invasive brain procedures, developed at its Sheikh Zayed Institute, which suggests the startup's concept may be grounded in translational research rather than software-only positioning [Children's National, retrieved 2026].

The evidence base is still early, and that matters more here than in a pure software company. A LinkedIn post cited in the research described a "first-of-its-kind" robot operating inside an MRI, but that is still social or investor-adjacent evidence rather than a verified commercial deployment or regulatory milestone [LinkedIn, retrieved 2026]. Public sources reviewed for this section do not establish FDA clearance, named hospital customers, or commercial use, so the current read is a technically ambitious platform with some external research support, but limited public validation on clinical workflow, reliability, or adoption.

Partially corroborated -- Product scope is described primarily by company materials, with partial corroboration from Communications Engineering and Children's National.

Market Research

PUBLIC

This market matters now because the bottleneck in brain therapeutics is shifting from discovery toward delivery, and 4D Surgical is explicitly aimed at that access layer rather than at any single drug or device program [4D Surgical, retrieved 2026].

The public record does not support a direct TAM, SAM, or SOM estimate for MRI-compatible brain robotics, so the cleanest way to frame the opportunity is through adjacent markets rather than invented precision. On the demand side, 4D Surgical positions its platform around minimally invasive, image-guided brain procedures and the delivery of electrodes, drugs, devices, and gene therapies, which places it at the intersection of neurosurgery, interventional imaging, and advanced therapeutics delivery [4D Surgical, retrieved 2026]. That is a meaningful wedge if the workflow proves viable, because it ties the company to procedure growth in stereotactic neurosurgery and to the broader rise of therapies that need accurate intracranial placement, but the current sources do not quantify those procedure volumes or spending pools.

The same evidence also points to a broader adjacent market than classic surgical robotics. The company's own materials emphasize live MRI feedback and operation inside a scanner, while external descriptions link the underlying BrainBot work to Children’s National Hospital and to MRI-guided minimally invasive brain procedures [4D Surgical, retrieved 2026] [Children's National Research and Innovation, retrieved 2026] [Children's National, retrieved 2026]. That suggests the relevant comparison set includes not only robotic surgery platforms, but also image-guided intervention systems, neuronavigation tools, stereotactic frames, and delivery systems for neurotherapeutics. In practical terms, the bet is that a platform that expands physical access to the brain could capture value across several existing budgets instead of relying on a single equipment line item.

Demand drivers in the cited material are mostly clinical and technical, not cyclical. 4D Surgical argues that new gene therapies, cell therapies, and brain-computer interfaces increase the need for precise access to the brain, and that conventional robotic systems cannot safely function inside MRI environments because of magnetic interference [4D Surgical, retrieved 2026]. A peer-reviewed description of related work by Lorne Hofstetter and colleagues is directionally supportive here: Communications Engineering reported that the team designed a servomotor from non-magnetic components and tested it in a robot operating in a clinical MRI during imaging [Communications Engineering, retrieved 2026]. That does not validate commercial demand, but it does support the underlying thesis that MRI compatibility is a real technical constraint and not a marketing abstraction.

Regulation is likely to shape adoption as much as clinical interest. Axios Pro reported in November 2026 that 4D Surgical planned a $30 million financing in the second half of 2027 to help begin the FDA-clearance process, with the system still pre-commercial at the time of reporting [Axios Pro, November 2026]. For investors, that matters more than top-down market language: a large theoretical need in neurosurgery or brain therapeutics does not convert into usable revenue until the company can navigate clearance, workflow integration, and hospital capital budgeting. The near-term market, then, is better read as an emerging enabling-tools market for MRI-guided neurointerventions than as a mature surgical robotics category.

Market lens Public evidence Read-through for 4D Surgical
Brain therapeutics delivery 4D Surgical frames the platform around delivering electrodes, drugs, devices, and gene therapies within the brain [4D Surgical, retrieved 2026] Supports a platform thesis tied to multiple therapy modalities rather than one procedure alone
MRI-guided intervention The product is described as an MRI-compatible robotic arm for live image-guided brain procedures [4D Surgical, retrieved 2026] [Children's National Research and Innovation, retrieved 2026] Places the company in an imaging-plus-intervention budget discussion, not only in robotics
Stereotactic neurosurgery The initial use case is stereotactic neurosurgery with live MRI feedback [4D Surgical, retrieved 2026] Gives the company a narrower first wedge, though public sources do not yet quantify procedure volume
Regulatory pathway FDA-clearance work is reported as a future step tied to later financing [Axios Pro, November 2026] Implies the addressable commercial market remains contingent on clearance and clinical validation

The table underscores the central market feature here: the opportunity is easiest to understand as overlap between neurotherapeutics delivery, MRI-guided intervention, and stereotactic workflow, while the investable market remains gated by regulation and adoption evidence. That framing is narrower than a generic surgical robotics story, but it is also more defensible on the public record.

Claim stands unchecked -- This section relies primarily on company materials for market framing, with limited independent support from Children’s National, Communications Engineering, and Axios Pro for adjacent context and regulatory timing.

Competition and Substitutes

Reported and inferred The company is positioned less against a single named startup peer than against three established alternatives: frame-based stereotactic workflows, navigation-heavy neurosurgical systems used outside the MRI bore, and the broader class of surgical-robotics platforms that stop short of real-time MRI-guided brain access [4D Surgical, retrieved 2026] [Communications Engineering] [Axios Pro, November 2026].

The public record is thin on direct head-to-head competitors, which matters here because the competitive map is defined more by workflow substitution than by a clean startup cohort. On one side sit incumbent neurosurgical approaches for stereotactic access, which already have surgeon familiarity, hospital budgeting pathways, and procedural history. On another sit adjacent robotics and image-guidance systems from larger medtech players, including the background networks represented by Intuitive Surgical and Johnson & Johnson in co-founder Roman Devengenzo's prior experience, even though the sources do not establish those companies as direct competitors to 4D Surgical's current product [4D Surgical, retrieved 2026] [LinkedIn, retrieved 2026]. A third lane is academic and translational research around MRI-compatible intervention, where BrainBot at Children's National appears closest in technical adjacency because it is also described as an MRI-compatible robotic system for minimally invasive brain procedures [Children's National Research and Innovation, retrieved 2026] [Children's National, retrieved 2026].

Where 4D Surgical appears strongest today is at the intersection of technical specialization and founder-market fit, not distribution. The clearest public support for that view is the underlying research record: Lorne Hofstetter and colleagues reported designing a non-magnetic electromagnetic servomotor and testing it in a robot operating in a clinical MRI during imaging, which speaks to a hard engineering problem rather than a software-layer refinement [Communications Engineering]. The company also frames its initial wedge narrowly, stereotactic neurosurgery with live MRI feedback, which is strategically sensible because it limits the product claim to a setting where MRI compatibility is central rather than incidental [4D Surgical, retrieved 2026]. That edge is real but perishable. It becomes durable only if the company can translate lab-grade technical novelty into regulatory progress, surgeon adoption, and repeatable hospital integration before larger device companies or hospital-based research groups close the gap [Axios Pro, November 2026].

The main exposure is that a technically novel platform can still lose to entrenched clinical workflow. BrainBot is the only named adjacent platform in the source set, and its advantage is not commercial scale but institutional provenance through Children's National and the Sheikh Zayed Institute, which can matter in early clinical credibility and investigator access [Children's National, retrieved 2026] [ACS, March 2026]. Outside that lane, incumbents in neurosurgical tools and operating-room robotics hold the practical advantage of installed relationships, service infrastructure, and capital base, even where the retrieved sources do not tie them directly to MRI-bore robotics. 4D Surgical also does not yet appear to own a distribution channel, a named hospital network, or public evidence of commercial deployment, and Axios Pro reported that FDA-clearance work is still ahead of the company rather than behind it [Axios Pro, November 2026].

The most plausible 18-month scenario is a bifurcation between technical proof and commercial proof. Winner if X: BrainBot, if hospital-affiliated MRI-compatible robotics programs convert earlier into formal clinical studies or institutional partnerships, because that route may produce credibility before startup sales infrastructure exists [Children's National Research and Innovation, retrieved 2026] [Children's National, retrieved 2026]. Loser if Y: 4D Surgical, if the planned 2027 financing slips or closes below plan, because Axios Pro tied the next capital raise to the start of the FDA-clearance process, making capital availability a direct competitive variable rather than a background one [Axios Pro, November 2026]. The upside case for 4D Surgical is still visible in public materials, but the current contest looks less like brand competition and more like a race to turn MRI-compatible robotics from a research milestone into a regulated product.

Partially corroborated -- Based on one independent news report, one academic source, and company or institution-backed materials; the section's key competitive premises are only partially corroborated in public sources.

Opportunity

PUBLIC

The prize here is large because a robot that can work safely inside an MRI could become enabling infrastructure for a broader class of brain interventions, not just a single neurosurgical tool, if 4D Surgical can translate an early technical proof point into regulatory clearance and clinical adoption [4D Surgical, retrieved 2026] [Version One Ventures, November 2026] [Communications Engineering].

The headline opportunity is straightforward: 4D Surgical could become the platform company for MRI-guided access to the brain, with an initial wedge in stereotactic neurosurgery and a longer arc into delivery of electrodes, drugs, devices, and gene therapies [4D Surgical, retrieved 2026]. That outcome is still conditional, but it is not detached from the evidence. Public materials describe a system built specifically for the MRI environment, where conventional robotic systems face magnetic interference constraints, and investor materials tied to the November 2026 seed round frame the product as a first-of-its-kind robotic arm system operating inside an MRI [4D Surgical, retrieved 2026] [Version One Ventures, November 2026]. The technical lineage also matters. A published research record states that Lorne Hofstetter and colleagues designed a servomotor from non-magnetic components and tested it in a robot operating in a clinical MRI during imaging, which is a more concrete foundation than a purely conceptual device claim [Communications Engineering].

The upside case rests on a narrow but meaningful proposition: if MRI-compatible actuation is hard and clinically useful, the first company to package it into a repeatable procedural platform may control an important interface between imaging, access, and therapy delivery. That is why the company's language around "universal physical access to the brain" deserves attention even if it remains company-defined for now [4D Surgical, retrieved 2026]. The important distinction is that 4D Surgical is not pitching general-purpose surgical robotics in the abstract. The public evidence points to a specific technical constraint, a specific procedural setting, and a specific initial use case in MRI-guided stereotactic brain procedures [4D Surgical, retrieved 2026] [Axios Pro, November 2026].

Scenario What happens Catalyst Why it's plausible
MRI-guided neurosurgery wedge 4D Surgical wins clearance for an initial stereotactic brain workflow and becomes the reference platform for MRI-guided minimally invasive intracranial access in leading centers The planned 2027 financing supports the FDA-clearance process, with Axios Pro reporting a path aimed at completion by late 2028 The company is already organized around this exact first indication, and the underlying MRI-operable robotics concept is supported by both company materials and a published engineering record [Axios Pro, November 2026] [4D Surgical, retrieved 2026] [Communications Engineering]
Therapy delivery platform The robot expands from access into a delivery layer for electrodes, drugs, devices, and gene therapies, increasing value per installed system and broadening clinical relevance A first approved or clinically adopted therapy that benefits from precise MRI-guided delivery turns the robot from capital equipment into procedural infrastructure Public materials explicitly position the system for multiple payload types, not only one surgical motion, which creates a plausible expansion path if the first workflow works in practice [4D Surgical, retrieved 2026]
MRI-native robotics standard 4D Surgical becomes the default partner for institutions or developers that need intervention inside the MRI bore, giving it a standards-like role in a technically constrained environment Independent validation of in-MRI performance and early institutional adoption establish the company as the practical route into this workflow category Investor and research descriptions both point to the same core claim, that operating safely inside a clinical MRI is unusual and technically non-trivial, which is the sort of constraint that can produce category concentration if solved early [Version One Ventures, November 2026] [Children's National, retrieved 2026] [Communications Engineering]

What compounding looks like is less about a classic consumer network effect and more about workflow lock-in. If one MRI-guided brain procedure gains traction, the same installed base could support adjacent interventions that use the same physical access stack, planning software, and operating model [4D Surgical, retrieved 2026]. That matters because hospitals do not usually buy procedural robotics for one theoretical future use. They buy around a workflow, then expand utilization if the platform proves safe, useful, and adaptable. The company's own product framing already points toward that adjacency map, from stereotactic procedures to delivery of other therapies into the brain [4D Surgical, retrieved 2026].

There is also a technical compounding path if the company can convert prototype performance into a differentiated procedural dataset. Real-time MRI-guided intervention could, in principle, generate proprietary information around targeting, motion control, and workflow optimization, though the public record does not yet show that this loop is active in clinical use. Even so, the published motor and in-MRI robot work, together with the BrainBot research lineage at Children's National, suggest the company is building on more than branding alone [Communications Engineering] [Children's National Research and Innovation, retrieved 2026] [ACS, March 2026]. In medical robotics, that kind of accumulated systems know-how can compound because each validated step raises the barrier for later entrants.

The size of the win is hard to benchmark precisely from the public record because no market-size figure or direct public comparable was provided in the source set. The most defensible way to frame it is by platform breadth rather than near-term revenue. If the "therapy delivery platform" scenario plays out, 4D Surgical would not be selling only a robot for one procedure. It would be positioning itself at the point where imaging, navigation, and brain-directed therapeutics meet, which could support a venture-scale outcome well beyond a single-product device company (scenario, not a forecast) [4D Surgical, retrieved 2026] [Version One Ventures, November 2026]. The public evidence is still early and company-weighted, so the upside case depends heavily on future proof through clearance, named clinical users, and repeated procedural evidence. But the core claim is credible enough to keep the opportunity unusually large for a seed-stage medical robotics company.

Partially corroborated -- Based on one independent financing report, one investor announcement, and company materials, with technical support from published and institutional sources but limited public clinical or commercial validation.

Sources

Open sources

  1. [4D Surgical, retrieved 2026] 4D Surgical | https://www.4dsurgical.com/

  2. [Crunchbase] 4D Surgical | https://www.crunchbase.com/organization/4d-surgical

  3. [Version One Ventures, November 2026] Announcing our investment in 4D Surgical, the platform for universal brain access | https://www.versionone.com/

  4. [Axios Pro, November 2026] Exclusive: 4D Surgical eyes $30M raise next year | https://www.axios.com/pro

  5. [LinkedIn, retrieved 2026] 4D Surgical | https://www.linkedin.com/company/4d-surgical

  6. [Communications Engineering, retrieved 2026] Communications Engineering | https://www.nature.com/commseng/

  7. [Lorne Hofstetter - 4D Surgical | LinkedIn, retrieved 2026] Lorne Hofstetter | https://www.linkedin.com/in/lorne-hofstetter/

  8. [Roman Devengenzo - 4D Surgical | LinkedIn, retrieved 2026] Roman Devengenzo | https://www.linkedin.com/in/devengenzo/

  9. [Blake Zimmerman - 4D Surgical | LinkedIn, retrieved 2026] Blake Zimmerman | https://www.linkedin.com/in/blake-zimmerman-505947a4/

  10. [Inflect Capital] Why We Invested in 4D Surgical | https://inflectcapital.substack.com/p/why-we-invested-in-4d-surgical

  11. [Prospeo.io, retrieved 2026] 4D Surgical | https://www.prospeo.io/

  12. [Children's National, retrieved 2026] BrainBot | https://innovationdistrict.childrensnational.org/

  13. [Children's National Research and Innovation, retrieved 2026] Children's National Research and Innovation | https://innovationdistrict.childrensnational.org/

  14. [ACS, March 2026] American College of Surgeons | https://www.facs.org/

  15. [The New York Times, July 2012] Rachel Mount, Lorne Hofstetter | https://www.nytimes.com/2012/07/29/fashion/weddings/rachel-mount-lorne-hofstetter-weddings.html

Articles about 4D Surgical

View on Startuply.vc